Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milciclib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Tiziana Life Sciences

    • Most Recent Events

    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 14 May 2020 According to a Tiziana Lifesciences media release, the trial successfully met the primary endpoint that oral treatment with Milciclib was well tolerated with manageable toxicities and no recorded drug related deaths.
    • 14 May 2020 According to a Tiziana Lifesciences media release, the company today announced the online publication of an abstract (Abstract #298561) reporting phase IIa data from this trial in the proceedings of the virtual annual meeting of American Society of Clinical Oncology 2020 (ASCO20).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top